摘要
目的:观察重组人血管内皮抑素联合顺铂胸腔热灌注治疗恶性胸腔积液的临床疗效和不良反应。方法:将90例合并恶性胸腔积液患者随机分为2组,每组45例。A组重组人血管内皮抑素+顺铂联合组:胸腔热灌注术循环时胸腔内注入顺铂40mg,术毕胸腔内注入重组人血管内皮抑制素30mg,2次/周,连续3周;B组顺铂组:胸腔热灌注术循环时胸腔内注入顺铂40mg,2次/周,连续3周。评价近期疗效、生活质量及不良反应。结果:A组RR 86.67%,B组53.33%(P<0.01)。A组生活质量改善者32例(71.11%),B组19例(42.22%)(P<0.01)。结论:重组人血管内皮抑素联合顺铂胸腔热灌注治疗恶性胸腔积液疗效显著,可明显改善患者的生活质量,不良反应小。
Objective：To evaluate the clinical efficacy and side effects of endostar combined with cisdiammi dichloride platinum （DDP） in the treatment of non-small cell lung cancer （NSCLC） with malignant pleural effusion （MPE）.Methods：Ninety NSCLC patients with pleural effusion were equally randomized into combination group （endostar combined with DDP） and DDP group.The combination group A was performed intrapleural injection of endostar （30mg,twice a week） and DDP （40mg,twice a week for 3 weeks）.The control group B was only given intrapleural injection of DDP （40mg,twice a week for 3 weeks）.The efficacy,quality of life （QOL）,safety and adverse events were evaluated.Results：The recovery rate （RR） of the combination group was 86.67％,B group was 53.33％ （P ＜0.01）.Thirty-two （71.11％） patients in the combination group QOL was improved,while the other group was 19 patients （42.22％） in the control group （P ＜0.01）.Conclusion：Intrapleural injection of endostar combined with DDP is a safe and feasible way to treat NSCLC with MPE.
出处
《现代肿瘤医学》
CAS
2013年第11期2485-2487,共3页
Journal of Modern Oncology
